The March mayhem that saw domestic benchmark indices tank 24% in not behind investors despite a decent recovery in the month of April. However, the coming few months could be crucial for investors.

In the wake of Franklin Templeton wounding up six of its debt mutual fund schemes, India’s largest mutual fund distributors body has urged the Reserve Bank of India to set up a SPV to buy portfolios from troubled fund houses and pay off investors.

Market regulator SEBI, late Thursday night advised Franklin Templeton to focus on returning investor’s money after the fund house decided to wound up six of its debt mutual fund schemes.

HCL Technologies posted strong March quarter numbers with revenue increasing by 16% on-year basis and PAT jumping 22.7% in the same time period. The stock has surged 27% from recent lows and is now down just 10% year-to-date.

Last month, the fund house had closed six of its debt funds, citing redemption pressures and lack of liquidity in the bond markets. 

Cash flows will be tight and they may also experience delay in the investment cycle, but this is a temporary phase, says Bhaskar Majumdar, managing partner, Unicorn India Ventures (UIV), a Mumbai-based fund house.

A proxy advisory firm has raised objections to the corporate governance structure at Zee Learn, part of the Essel group, expressing concerns over the company’s capital allocation decision, related-party transactions and acquisition of MT Educare.

India’s share of world manufacturing output is just 3%; it can easily be raised to 6% in 3-4 years, and 15% by 2030

With China’s decreasing importance in global supply chains, being a low risk indexed location will allow India to win in global manufacturing stakes.

PM Modi said that the action should be taken for a more proactive approach to handhold the investors.

After a lifetime high FPI withdrawal in the month of March, the foreign portfolio investors have once again pulled out nearly Rs 15,000 crore from the country's capital market in April.

The U.K. Green Investment Bank is set to tie up the first investments in a $1.6 billion fund by the end of March, part of Britain’s push to cement its dominance in offshore wind power.

Investors have spent more than $2 trillion on clean-energy plants in the past decade and last year added more renewable capacity than ever before.

Wind farms and solar parks are changing hands at record rates, signaling both an increased taste for the assets among pension funds and hard times for utilities that are the biggest sellers.

Simplifying finance vehicles for renewable energy will lure more investors and lower the costs of capital.

The U.K. Green Investment Bank is set to tie up the first investments in a $1.6 billion fund by the end of March, part of Britain’s push to cement its dominance in offshore wind power.

Investors have spent more than $2 trillion on clean-energy plants in the past decade and last year added more renewable capacity than ever before.

All of the proceeds raised through the Ray of Hope platform will go directly to Beyond Social Services charity's COVID-19 Family Assistance Fund. 

The post Singapore venture investors, startup founders raising funds for low-income families appeared first on DealStreetAsia.

Startups in health care and deliveries have managed to raise millions to accelerate their expansion.

The post Southeast Asia’s healthcare startups attract wary investors appeared first on DealStreetAsia.

Measures announced by the govt, such as tax and loan deferments, are unlikely to boost VC investments.

The post Malaysia’s latest stimulus package gets thumbs down from businesses, investors appeared first on DealStreetAsia.

This book covers seed stage financing for high-growth companies in OECD and non-OECD countries with a primary focus on angel investment. It provides an overview of angel financing, including a description of how it has evolved and policy interventions taken within some countries.

Promoting responsible business conduct in the financial sector is vital to building a sustainable global economy. This paper will help institutional investors implement the due diligence recommendations of the OECD Guidelines for Multinational Enterprises in order to prevent or address adverse impacts related to human and labour rights, the environment, and corruption in their investment portfolios.

This joint OECD-UNIDO report identifies investment and related policies to enhance linkages between small and medium-sized enterprises (SMEs) in Southeast Asia and multinational enterprises (MNEs) and their impacts on SME outcomes in Southeast Asia.

This report brings together data on patents, trademarks and scientific publications of the world’s top corporate R&D investors to shed light on the role of these key players in shaping the future of technologies, artificial intelligence in particular.

Co-organised by the G20 Russian Presidency and the OECD, this roundtable focused on policy measures to address constraints in long-term investment. It was organised back-to-back with the 2013 OECD Forum and the OECD-Euromoney Infrastructure Summit.

This G20 report looks at the evolution of private institutional investment in infrastructure and examines how the market has developed; analyses various investment vehicles with a snapshot of the growth experienced in the market; categorises methods used for investing in infrastructure; and, highlights the challenges and barriers to investment.

This brochure provides information about the OECD Project on Institutional Investors and Long-term Investment. It covers the first two years of activity following the launch of the project in February 2012. This project aims to facilitate long-term investment by institutional investors such as pension funds, insurance companies, and sovereign wealth funds, addressing both potential regulatory obstacles and market failures.

Singapore, 4 June 2014: This roundtable focused on how policymakers and investors can facilitate private sector infrastructure financing, as well as issues related to governance for institutional investors and the accounting treatment for long-term investment.

Singapore, 28 May 2015: This roundtable will focus on key themes related to G20 work, including how policy makers and investors can facilitate private sector infrastructure financing, the development of infrastructure as an asset class, and issues relating to the regulation of long-term investment.

Singapore, 25 April 2016: This roundtable focused on key themes related to G20 work, in particular the views of the private sector on current work developed by the OECD for the G20 Presidency toward promoting more diversified and innovative infrastructure financing.

Promoting responsible business conduct in the financial sector is vital to building a sustainable global economy. This paper will help institutional investors implement the due diligence recommendations of the OECD Guidelines for Multinational Enterprises in order to prevent or address adverse impacts related to human and labour rights, the environment, and corruption in their investment portfolios.

11 December 2017, OECD Paris - The 8th annual OECD high-level breakfast event brings together leading investors and senior government officials for informal, focused dialogue, to examine key developments and identify solutions to enable achievement of NDCs and the two-degree commitment.

One focus of tomorrow’s One Planet Summit, organised by President Macron, is “to determine how those working in public and private finance can innovate to support and accelerate our common efforts to fight climate change.”

On 10 December in Katowice, the 9th annual High-Level Breakfast on Institutional Investors and the Low-carbon Transition, co-hosted by the OECD and the Institutional Investors Group on Climate Change (IIGCC), highlighted significant progress in mobilising green institutional investment, as well as important remaining challenges.

This publication examines the role of institutional investors in promoting good corporate governance and reviews Australia, Chile and Germany in more detail.

Guidelines for investors concerned about volatility

Before we head on to answer your queries on your investments in mutual fund schemes, here we clarify that last evening after the amc company Franklin Templeton was left with no option on barely any new subscription and other liquidity issues,

Charlie Munger, the vice-chairman of Berkshire Hathway, the investment company controlled by billionaire Warren Buffet, is not looking at making investments amid the COVID-19 crisis. In a recent telephonic interview with the Wall Street Journal, Munger was asked if his investment

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

When investors spend billions on baby boomer housing, is this smart money or is it missing the demographic boat?

Two guys peddled the idea of making money with renewable energy and biochar but ultimately ended up just taking their investors for millions.

US SIF and investors representing more than $30B in assets submitted a letter to the Department of the Interior opposing its proposal for coastal oil development

Peppybox, a legally-operating online marketplace for cannabis delivery has recently announced that celebrity angel investors have shown interest to fund its business and to champion it using their own personal branding.

Nigeria Off Grid Sector Advances